TBVAC-HORIZON Improving understanding of lung immunity in tuberculosis to establish a diverse, innovative TB vaccine pipeline targeting mucosal immunity

TBVAC-HORIZON 提高对结核病肺免疫的了解，建立针对粘膜免疫的多样化、创新型结核疫苗管道

• 批准号: 10078410
• 金额: $ 29.35万
• 依托单位: MEDICINES AND HEALTHCARE REGULATORY PRODUCTS AGENCY
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10078410
• 关键词: TBVAC; HORIZON; Improving; understanding; lung

Tuberculosis (TB) remains one of the most devastating infectious diseases worldwide, killing over 4,000 people every day. Prevention of tuberculosisinfection by novel vaccines would provide the most cost-effective approach to achieve the goals of the WHO End TB strategy and the Sustainable Development Goals of the United Nations. While there are few promising TB vaccine candidates available, innovation by new platforms and strategies is needed to ensure that the most effective and affordable vaccines are developed. TBVACHORIZON will innovate and diversify the global TB vaccine pipeline by pursuing four objectives: 1. Define the composition, spatial organisation and functioning of protective immune responses in the Mycobacterium tuberculosis-infected lung. 2. Evaluate whether mucosal re vaccination with BCG and other live attenuated vaccines improves protective efficacy against tuberculosis infection in mice, non-human primates and humans. 3. Identify host immune response profiles and biomarkers of natural and vaccine-induced immune protection in the lung. 4. Support next generation TB vaccine development by standardised head-to-head testing of selected vaccine candidates in animals and the establishment of novel delivery systems, adjuvant formulations and GMP platforms for live attenuated vaccines. TBVACHORIZON will increase our understanding and develop tools pertaining to immune protection in the lung, the major site of tuberculosis infection. This knowledge will be exploited to develop mucosal strategies for translating towards clinical evaluation and possible implementation. The interwoven activities will consolidate Europe’s leading role in TB vaccine research and innovation, with the ultimate goal of accelerated availability of affordable, accessible and more effective TB vaccines.

结核病 (TB) 仍然是全世界最具破坏性的传染病之一，每天导致 4,000 多人死亡，通过新型疫苗预防结核感染将为实现世卫组织消除结核病战略和可持续发展目标提供最具成本效益的方法。虽然有希望的结核病候选疫苗很少，但需要通过新平台和战略进行创新，以确保开发出最有效和负担得起的疫苗。通过追求四个目标来建立全球结核病疫苗管道： 1. 确定结核分枝杆菌感染的肺部保护性免疫反应的组成、空间组织和功能 2. 评估粘膜再接种卡介苗和其他减毒活疫苗是否可以提高预防效果。小鼠、非人类灵长类动物和人类的结核感染 3. 确定宿主免疫反应特征以及肺部自然和疫苗诱导免疫保护的生物标志物 4. 支持下一步。通过在动物体内对选定的候选疫苗进行标准化的头对头测试来开发新一代结核病疫苗，并为减毒活疫苗建立新型递送系统、佐剂配方和 GMP 平台，将增加我们对免疫保护的了解并开发相关工具。肺是结核病感染的主要部位，这些知识将被用来开发粘膜策略，以转化为临床评估和可能的实施，这些相互交织的活动将巩固欧洲在结核病疫苗研究和实施方面的领先地位。创新，最终目标是加速提供负担得起、容易获得和更有效的结核病疫苗。